|
|
|
RENAL GLUCOSE REABSORPTION:
AN EMERGING TARGET IN THE TREATMENT
OF TYPE 2 DIABETES MELLITUS
Strauss 1 Hall
| Tuesday, 29 September 2009, 10:00 - 12:30 |
 |
Webcast available 
| Chairs: |
John Wilding, UK
Scott C. Thomson, US
|
| 10:00 - 10:05 |
Welcome
Chair
|
| 10:05 - 10:30 |
Renal glucose reabsorption: a rational target
for the treatment of type 2 diabetes mellitus
Guntram Schernthaner, AT
|
| 10:30 - 10:55 |
A history of SGLT2 inhibition
John Gerich, US
|
| 10:55 - 11:20 |
SGLT2 inhibition in animal models –
building a basis of understanding
Jean Whaley, US
|
| 11:20 - 11:45 |
Dapagliflozin in patients with type 2 diabetes mellitus
– what is the evidence?
John Wilding, UK
|
| 11:45 - 12:15 |
Panel discussion: “What role will SGLT2 inhibitors
have in the treatment of type 2 diabetes mellitus?“
Scott C. Thomson, US
|
| 12:15 - 12:20 |
Concluding remarks
Chair |
For further information please contact:
Steven J Wieland, PhD
Research and Development
AstraZeneca
mailto:steve.wieland@astrazeneca.com
Websites: www.astrazeneca.com & www.bms.com
Sponsors: and
 
|
|
 |
|
Symposia Programme
